| Literature DB >> 24666594 |
Sarah Gimbel1, Joachim Voss2, Alison Rustagi3, Mary Anne Mercer3, Brenda Zierler4, Stephen Gloyd5, Maria de Joana Coutinho6, Maria de Fatima Cuembelo7, Kenneth Sherr5.
Abstract
INTRODUCTION: Efforts to implement and take to scale highly efficacious, low-cost interventions to prevent mother-to-child HIV transmission (pMTCT) have been a cornerstone of reproductive health services in sub-Saharan Africa for over a decade. Yet efforts to increase access and utilization of these services remain far from optimal. This study developed and applied an approach to systematically classify pMTCT performance to identify modifiable health system factors associated with pMTCT performance which may be replicated in other pMTCT systems.Entities:
Keywords: Mozambique; PMTCT; health systems strengthening; implementation science; performance classification; performance measures
Mesh:
Substances:
Year: 2014 PMID: 24666594 PMCID: PMC3965711 DOI: 10.7448/IAS.17.1.18828
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Ranking measures
| Indicator | Pros | Cons | |
|---|---|---|---|
| 1 | % of women with HIV test at first ANC Visit | High availability and standardized collection and reporting across facilities | Little heterogeneity; almost universally high masks performance differences |
| 2 | % of pregnant women with positive HIV test at first ANC visit with a CD4 test while in pregnancy | Measures integration across services (e.g. laboratory vs. clinic), high variation across facilities | Data inconsistent or unavailable; cannot link women with outcome to those with HIV test at first ANC visit using routinely reported data |
| 3 | % of pregnant women with a positive HIV test at first visit who initiate either bi-/tri-prophylaxis or cART prior to delivery | High availability and standardized collection and reporting across facilities | Cannot link women with outcome to those with HIV test at first ANC visit using routinely reported data |
ANC: antenatal care; cART: combination antiretroviral therapy.
Characteristics of study slinics
|
| % | |
|---|---|---|
| Clinic location | ||
| Rural | 18 | 60 |
| Urban | 5 | 17 |
| Peri-urban | 7 | 23 |
| Clinic type | ||
| Quaternary/tertiary | 1 | 3 |
| Secondary | 1 | 3 |
| Primary | 28 | 93 |
| Public/private | ||
| Public | 27 | 90 |
| Private | 0 | 0 |
| Mixed | 3 | 10 |
| NGO support | ||
| None | 17 | 57 |
| One | 5 | 17 |
| Multiple | 8 | 26 |
| Year of pMTCT initiation | ||
| Before 2005 | 5 | 17 |
| Between 2006 and 2008 | 21 | 70 |
| After 2008 | 4 | 13 |
| Other characteristics | Mean | Median |
| Distance to reference laboratory (km) | 22 | 16 |
| Catchment population (people) | 27,774 | 19,644 |
| No. 1st ANC visits in the last 6 months | 674 | 468 |
| No. institutional births in the last 6 months | 482 | 257 |
| No. post-partum visits in the last 6 months | 418 | 189 |
NGO: non-governmental organization; pMTCT: prevention of mother-to-child-transmission; ANC: antenatal care.
Effect of PMTCT measurement strategy on performance ranking
| HIV testing, ART-PPO mother | HIV testing, CD4 testing, ART-PPO mother | ART-PPO mother | CD4 | HIV testing | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
| ||||||||||
| Rank | Clinic | Score | Rank | Clinic | Score | Rank | Clinic | Score | Rank | Clinic | Score | Rank | Clinic | Score |
| 1 | A | 0.958 | 1 | j | 0.745 | 1 | A | 0.947 | 1 | J | 0.611 | 1 | V | 1.00 |
| 2 | B | 0.941 | 2 | E | 0.723 | 2 | B | 0.923 | 2 | E | 0.442 | 2 | Q | 1.00 |
| 3 | C | 0.902 | 3 | A | 0.705 | 3 | C | 0.870 | 3 | N | 0.396 | 3 | Z | 1.00 |
| 4 | D | 0.864 | 4 | B | 0.627 | 4 | I | 0.796 | 4 | K | 0.310 | 4 | L | 1.00 |
| 5 | E | 0.863 | 5 | K | 0.620 | 5 | G | 0.788 | 5 | A | 0.200 | 5 | E | 1.00 |
| 6 | F | 0.862 | 6 | N | 0.620 | 6 | F | 0.788 | 6 | M | 0.165 | 6 | O | 1.00 |
| 7 | G | 0.857 | 7 | I | 0.610 | 7 | H | 0.782 | 7 | I | 0.124 | 7 | D | 1.00 |
| 8 | H | 0.856 | 8 | G | 0.603 | 8 | D | 0.727 | 8 | G | 0.096 | 8 | J | 1.00 |
| 9 | I | 0.853 | 9 | C | 0.601 | 9 | E | 0.726 | 9 | S | 0.078 | 9 | K | 0.98 |
| 10 | J | 0.813 | 10 | F | 0.586 | 10 | M | 0.647 | 10 | L | 0.056 | 10 | U | 0.98 |
| 11 | K | 0.776 | 11 | D | 0.576 | 11 | J | 0.628 | 11 | BB | 0.043 | 11 | A | 0.97 |
| 12 | L | 0.761 | 12 | H | 0.571 | 12 | K | 0.567 | 12 | F | 0.034 | 12 | S | 0.96 |
| 13 | M | 0.749 | 13 | M | 0.554 | 13 | N | 0.561 | 13 | R | 0.024 | 13 | B | 0.96 |
| 14 | N | 0.732 | 14 | L | 0.526 | 14 | P | 0.547 | 14 | AA | 0.007 | 14 | DD | 0.95 |
| 15 | O | 0.727 | 15 | S | 0.492 | 15 | T | 0.545 | 15 | H | 0.000 | 15 | Y | 0.95 |
| 16 | P | 0.726 | 16 | O | 0.484 | 16 | R | 0.540 | 16 | Q | 0.000 | 16 | F | 0.94 |
| 17 | Q | 0.714 | 17 | P | 0.484 | 17 | X | 0.524 | 17 | Z | 0.000 | 17 | C | 0.93 |
| 18 | R | 0.713 | 18 | R | 0.483 | 18 | L | 0.521 | 18 | B | 0.000 | 18 | H | 0.93 |
| 19 | S | 0.699 | 19 | Q | 0.476 | 19 | O | 0.453 | 19 | CC | 0.000 | 19 | G | 0.92 |
| 20 | T | 0.691 | 20 | T | 0.461 | 20 | S | 0.436 | 20 | O | 0.000 | 20 | I | 0.91 |
| 21 | U | 0.671 | 21 | U | 0.447 | 21 | Q | 0.429 | 21 | U | 0.000 | 21 | W | 0.91 |
| 22 | V | 0.669 | 22 | V | 0.446 | 22 | W | 0.396 | 22 | W | 0.000 | 22 | P | 0.91 |
| 23 | W | 0.652 | 23 | W | 0.434 | 23 | V | 0.367 | 23 | P | 0.000 | 23 | N | 0.90 |
| 24 | X | 0.640 | 24 | X | 0.427 | 24 | Y | 0.308 | 24 | T | 0.000 | 24 | AA | 0.90 |
| 25 | Y | 0.627 | 25 | Y | 0.418 | 25 | AA | 0.304 | 25 | X | 0.000 | 25 | CC | 0.89 |
| 26 | Z | 0.615 | 26 | Z | 0.410 | 26 | BB | 0.275 | 26 | Y | 0.000 | 26 | R | 0.89 |
| 27 | AA | 0.600 | 27 | AA | 0.402 | 27 | Z | 0.229 | 27 | DD | 0.000 | 27 | BB | 0.88 |
| 28 | BB | 0.579 | 28 | BB | 0.401 | 28 | CC | 0.095 | 28 | V | 0.000 | 28 | M | 0.85 |
| 29 | CC | 0.494 | 29 | CC | 0.329 | 29 | DD | 0.000 | 29 | C | 0.000 | 29 | T | 0.84 |
| 30 | DD | 0.477 | 30 | DD | 0.318 | 30 | V | 0.000 | 30 | D | 0.000 | 30 | X | 0.76 |
Dark grey: high performance; white: middle performance; spotted grey: low performance using dual HIV testing & ART-PPO mother ranking schema; HIV: human immunodeficiency virus; ART: antiretroviral therapy; PPO: prophylaxis; CD4: cluster of differentiation 4.
Clinic characteristics associated with high pMTCT performance by ranking approach
| Ranking measure | +Association |
| −Association |
| No association |
|
|---|---|---|---|---|---|---|
| HIV test at first ANC visit & PPO-ART for mother | Catchment size | 0.01 | Wait time between PCR blood draw & receipt of results at facility | 0.04 | Clinic location (rural, urban, peri-urban) | 0.29 |
| No. MCH nurses | <0.01 | NGO support | 0.17 | |||
| No. MDs & NPCs | <0.02 | Active tracing LTFU | 0.52 | |||
| PIMA CD4 analyses at facility | <0.04 | HIV+ mothers support group at facility | 0.19 | |||
| No. of deliveries in prior 6 months | <0.01 | Community linkages | 0.43 | |||
| Schedule of receiving requisitions & delivering consumables | 0.36 | |||||
| ANC stock outs of: | ||||||
| AZT | 0.79 | |||||
| HIV rapid test | 0.59 | |||||
| Pharmacy stock outs of: | ||||||
| HIV rapid test | 0.79 | |||||
| PPO-ART for mother | Catchment size | <0.01 | Wait time between PCR blood draw and receipt of results at facility | <0.05 | Clinic location (rural, urban, peri-urban) | 0.37 |
| No. of MCH nurses | <0.01 | NGO support | 0.16 | |||
| No. of MDs & NPCs | 0.03 | Active tracing LTFU | 0.52 | |||
| PIMA CD4 analyses at facility | 0.04 | Community linkages | 0.66 | |||
| No. of deliveries in prior 6 months | <0.01 | Schedule of receiving requisitions & delivering consumables | 0.57 | |||
| HIV+ mothers support group at facility | <0.01 | ANC stock outs of: | ||||
| AZT | 0.79 | |||||
| HIV rapid test | 0.59 | |||||
| Pharmacy stock outs of: | ||||||
| HIV rapid test | 0.38 | |||||
| HIV test at first ANC visit | ANC stock outs of: | 0.04 | None | NA | Clinic location (rural, urban, peri-urban) | 0.42 |
| AZT | NGO support | 0.55 | ||||
| Active tracing LTFU | 0.52 | |||||
| Community linkages | 0.66 | |||||
| Schedule of receiving requisitions & delivering consumables | 0.16 | |||||
| ANC stock outs of: | ||||||
| HIV rapid test | 0.59 | |||||
| Pharmacy stock outs of: | ||||||
| HIV rapid test | 0.79 | |||||
| Catchment size | 0.83 | |||||
| No. of MCH nurses | 0.25 | |||||
| No. of MDs & NPCs | 0.61 | |||||
| PIMA CD4 analyses at facility | 0.33 | |||||
| No. of deliveries in prior 6 months | 0.80 | |||||
| HIV+ mothers support group at facility | 0.55 | |||||
| Wait time between PCR blood draw and receipt of results at facility | 0.37 |
All p-values are from chi-squared tests unless noted with *(unadjusted logistic regression).
PPO: prophylaxis; ART: antiretroviral therapy: ANC: antenatal care; MCH: maternal child health; MD: medical doctors; NPC: non physician clinicians; PIMA CD4: point of care rapid CD4; NGO: non-governmental organization; LTFU: lost to follow up; AZT: Zidovudine.
Associations of continuous clinic characteristics with performance, using different performance outcomes
| Three-level performance | Two-level performance (mid-performers omitted) | Two-level performance (low/middle vs. high) | Two-level performance (low vs. middle/high) | |||||
|---|---|---|---|---|---|---|---|---|
| Variable | Odds ratio (95% CI) | Odds ratio (95% CI) | Odds ratio (95% CI) | Odds ratio (95% CI) | ||||
| Catchment area (per 10,000 inhabitants) | 1.92 (1.09–3.38) | 0.02 | 3.57 (1.84–6.91) | 0.0002 | 1.47 (0.92–2.33) | 0.10 | 4.74 (1.46–15.36) | 0.01 |
| Wait time (days) between PCR blood draw & receipt of result at clinic | 0.95 (0.90–1.00) | 0.04 | 0.10 (0.01–1.41) | 0.09 | 0.96 (0.90–1.02) | 0.15 | 0.91 (0.83–1.00) | 0.05 |
| Number of MCH nurses | 1.12 (1.03–1.22) | 0.009 | 1.26 (1.08–1.47) | 0.003 | 1.08 (0.90–1.02) | 0.06 | 1.21 (1.05–1.41) | 0.01 |
| Number of MDs & NPCs | 2.21 (1.12–4.39) | 0.02 | 5.16 (1.22–21.86) | 0.03 | 2.00 (0.99, 4.01) | 0.05 | 5.37 (1.31–21.99) | 0.02 |
PCR: polymerase chain reaction; MCH: maternal child health; MD: medical doctors; NPCs=non-physician clinicians; *OR calculated using ordinal logistic regression with robust standard errors.